Hyperuricaemia, chronic kidney disease, and outcomes in heart failure: Potential mechanistic insights from epidemiological data

European Heart Journal

Volumn 32, Issue 6, 2011, Pages 712-720

  Filippatos, Gerasimos S ^a   Ahmed, Mustafa I ^b   Gladden, James D ^b   Mujib, Marjan ^b   Aban, Inmaculada B ^b   Love, Thomas E ^c   Sanders, Paul W ^b,d   Pitt, Bertram ^e   Anker, Stefan D ^f,g   Ahmed, Ali ^b,d  

^a UNIVERSITY OF ATHENS   (Greece)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c CASE WESTERN RESERVE UNIVERSITY   (United States)

^d BIRMINGHAM VA MEDICAL CENTER   (United States)

^e UNIVERSITY OF MICHIGAN   (United States)

^f CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^g IRCCS SAN RAFFAELE PISANA   (Italy)

Author keywords

Chronic kidney disease; Heart failure; Hyperuricaemia; Outcomes

Indexed keywords

ALLOPURINOL; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; BUCINDOLOL; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOOP DIURETIC AGENT; URIC ACID; VASODILATOR AGENT;

ADULT; ARTICLE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HOSPITALIZATION; HUMAN; HYPERURICEMIA; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK ASSESSMENT; SYSTOLIC HEART FAILURE; URIC ACID BLOOD LEVEL;

AGED; CANADA; CHRONIC DISEASE; FEMALE; GLOMERULAR FILTRATION RATE; HEART FAILURE; HOSPITALIZATION; HUMANS; HYPERURICEMIA; KAPLAN-MEIER ESTIMATE; KIDNEY DISEASES; MALE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; PROGNOSIS; PROPENSITY SCORE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; UNITED STATES; XANTHINE OXIDASE;

EID: 79952841631     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehq473     Document Type: Article

References (41)

1. Leyva F, Anker S, Swan JW, Godsland IF, Wingrove CS, Chua TP, Stevenson JC, Coats AJ. Serum uric acid as an index of impaired oxidative metabolism in chronic heart failure. Eur Heart J 1997;18:858-865. (Pubitemid 27208159)
2. DoehnerW, Rauchhaus M, Florea VG, Sharma R, Bolger AP, Davos CH, Coats AJ, Anker SD. Uric acid in cachectic and noncachectic patients with chronic heart failure: relationship to leg vascular resistance. Am Heart J 2001;141:792-799. (Pubitemid 32378489)
3. Anker SD, Doehner W, Rauchhaus M, Sharma R, Francis D, Knosalla C, Davos CH, Cicoira M, Shamim W, Kemp M, Segal R, Osterziel KJ, Leyva F, Hetzer R, Ponikowski P, Coats AJ. Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging. Circulation 2003;107:1991-1997. (Pubitemid 36506072)
4. Jankowska EA, Ponikowska B, Majda J, Zymlinski R, Trzaska M, Reczuch K, Borodulin-Nadzieja L, Banasiak W, Ponikowski P. Hyperuricaemia predicts poor outcome in patients with mild to moderate chronic heart failure. Int J Cardiol 2007;115:151-155. (Pubitemid 46136516)
5. Pascual-Figal DA, Hurtado-Martinez JA, Redondo B, Antolinos MJ, Ruiperez JA, Valdes M. Hyperuricaemia and long-term outcome after hospital discharge in acute heart failure patients. Eur J Heart Fail 2007;9:518-524. (Pubitemid 46561480)
6. Nugent CA, Tyler FH. The renal excretion of uric acid in patients with gout and in nongouty subjects. J Clin Invest 1959;38:1890-1898.
7. The Beta-Blocker Evaluation of Survival Trial Investigators. A trial of the betablocker bucindolol in patients with advanced chronic heart failure. N Engl J Med 2001;344:1659-1667.
8. Krishnan E, Kwoh CK, Schumacher HR, Kuller L. Hyperuricemia and incidence of hypertension among men without metabolic syndrome. Hypertension 2007;49: 298-303. (Pubitemid 46143005)
9. Akgul A, Bilgic A, Ibis A, Ozdemir FN, Arat Z, Haberal M. Is uric acid a predictive factor for graft dysfunction in renal transplant recipients? Transplant Proc 2007;39: 1023-1026. (Pubitemid 46764870)
10. Kawada T, Amezawa M. Effects of exercise and serum uric acid on the metabolic syndrome for Japanese workers. Metab Syndr Relat Disord 2008;6:137-141. (Pubitemid 351769261)
11. Culleton BF, Larson MG, Kannel WB, Levy D. Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann Intern Med 1999; 131:7-13. (Pubitemid 29310011)
12. Rosenbaum PR, Rubin DB. The central role of propensity score in observational studies for causal effects. Biometrika 1983;70:41-55.
13. Rubin DB. Using propensity score to help design observational studies: Application to the tobacco litigation. Health Serv Outcomes Res Methodol 2001;2: 169-188.
14. Ahmed A. A propensity matched study of New York Heart Association class and natural history end points in heart failure. Am J Cardiol 2007;99:549-553. (Pubitemid 46217880)
15. Ahmed A, Husain A, Love TE, Gambassi G, Dell'Italia LJ, Francis GS, Gheorghiade M, Allman RM, Meleth S, Bourge RC. Heart failure, chronic diuretic use, and increase in mortality and hospitalization: an observational study using propensity score methods. Eur Heart J 2006;27:1431-1439. (Pubitemid 43998077)
16. Rosenbaum PR. Sensitivity to hidden bias. In Rosenbaum PR, ed. Observational Studies. 2nd ed. New York: Springer-Verlag; 2002. p110-124.
17. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999;130:461-470. (Pubitemid 29135798)
18. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39:S1-266.
19. SPSS. SPSS for Windows, Rel. 15. Chicago, IL: SPSS Inc. 2008.
20. Chambers DE, Parks DA, Patterson G, Roy R, McCord JM, Yoshida S, Parmley LF, Downey JM. Xanthine oxidase as a source of free radical damage in myocardial ischemia. J Mol Cell Cardiol 1985;17:145-152. (Pubitemid 16241099)
21. de Jong JW, Schoemaker RG, de Jonge R, Bernocchi P, Keijzer E, Harrison R, Sharma HS, Ceconi C. Enhanced expression and activity of xanthine oxidoreductase in the failing heart. J Mol Cell Cardiol 2000;32:2083-2089.
22. Terada LS, Guidot DM, Leff JA, Willingham IR, Hanley ME, Piermattei D, Repine JE. Hypoxia injures endothelial cells by increasing endogenous xanthine oxidase activity. Proc Natl Acad Sci USA 1992;89:3362-3366.
23. Ahmed MI, Gladden JD, Litovsky SH, Lloyd SG, Gupta H, Inusah S, Denney T Jr, Powell P, McGiffin DC, Dell'Italia LJ. Increased oxidative stress and cardiomyocyte myofibrillar degeneration in patients with chronic isolated mitral regurgitation and ejection fraction .60%. J Am Coll Cardiol 2010;55:671-679.
24. Ekelund UE, Harrison RW, Shokek O, Thakkar RN, Tunin RS, Senzaki H, Kass DA, Marban E, Hare JM. Intravenous allopurinol decreases myocardial oxygen consumption and increases mechanical efficiency in dogs with pacing-induced heart failure. Circ Res 1999;85:437-445. (Pubitemid 29409620)
25. George J, Carr E, Davies J, Belch JJ, Struthers A. High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid. Circulation 2006;114:2508-2516. (Pubitemid 44901524)
26. Saliaris AP, Amado LC, Minhas KM, Schuleri KH, Lehrke S, St John M, Fitton T, Barreiro C, Berry C, Zheng M, Kozielski K, Eneboe V, Brawn J, Hare JM. Chronic allopurinol administration ameliorates maladaptive alterations in Ca2+ cycling proteins and beta-adrenergic hyporesponsiveness in heart failure. Am J Physiol Heart Circ Physiol 2007;292:H1328-1335. (Pubitemid 46377120)
27. Ukai T, Cheng CP, Tachibana H, Igawa A, Zhang ZS, Cheng HJ, Little WC. Allopurinol enhances the contractile response to dobutamine and exercise in dogs with pacing-induced heart failure. Circulation 2001;103:750-755. (Pubitemid 32144206)
28. Ogino K, Kato M, Furuse Y, Kinugasa Y, Ishida K, Osaki S, Kinugawa T, Igawa O, Hisatome I, Shigemasa C, Anker SD, Doehner W. Uric acid lowering treatment with benzbromarone in patients with heart failure: a double-blind placebocontrolled cross-over preliminary study. Circ Heart Fail 2010;3:73-81.
29. Hare JM, Mangal B, Brown J, Fisher C Jr, Freudenberger R, Colucci WS, Mann DL, Liu P, Givertz MM, Schwarz RP. Impact of oxypurinol in patients with symptomatic heart failure. Results of the OPT-CHF study. J Am Coll Cardiol 2008;51: 2301-2309. (Pubitemid 351783365)
30. Ekundayo OJ, Dell'italia LJ, Sanders PW, Arnett D, Aban I, Love TE, Filippatos G, Anker SD, Lloyd-Jones DM, Bakris G, Mujib M, Ahmed A. Association between hyperuricemia and incident heart failure among older adults: a propensitymatched study. Int J Cardiol 2009; Epub ahead of print; doi:10.1016/ j.ijcard 2009.
31. Desai RV, Ahmed MI, Fonarow GC, Filippatos GS, White M, Aban IB, Aronow WS, Ahmed A. Effect of serum insulin on the association between hyperuricemia and incident heart failure. Am J Cardiol 2010;106:1134-1138.
32. Facchini F, Chen YD, Hollenbeck CB, Reaven GM. Relationship between resistance to insulin-mediated glucose uptake, urinary uric acid clearance, and plasma uric acid concentration. J Am Med Assoc 1991;266:3008-3011.
33. Ochiai ME, Barretto AC, Oliveira MT Jr, Munhoz RT, Morgado PC, Ramires JA. Uric acid renal excretion and renal insufficiency in decompensated severe heart failure. Eur J Heart Fail 2005;7:468-474. (Pubitemid 40732973)
34. Chonchol M, Shlipak MG, Katz R, Sarnak MJ, Newman AB, Siscovick DS, Kestenbaum B, Carney JK, Fried LF. Relationship of uric acid with progression of kidney disease. Am J Kidney Dis 2007;50:239-247. (Pubitemid 47095076)
35. Quinones-Galvan A, Natali A, Baldi S, Frascerra S, Sanna G, Ciociaro D, Ferrannini E. Effect of insulin on uric acid excretion in humans. Am J Physiol 1995;268:E1-5.
36. Langford HG, Blaufox MD, Borhani NO, Curb JD, Molteni A, Schneider KA, Pressel S. Is thiazide-produced uric acid elevation harmful? Analysis of data from the Hypertension Detection and Follow-up Program. Arch Intern Med 1987;147:645-649. (Pubitemid 17063543)
37. Tykarski A. Evaluation of renal handling of uric acid in essential hypertension: hyperuricemia related to decreased urate secretion. Nephron 1991;59:364-368.
38. Navaneethan SD, Beddhu S. Associations of serum uric acid with cardiovascular events and mortality in moderate chronic kidney disease. Nephrol Dial Transplant 2009;24:1260-1266.
39. Farquharson CA, Butler R, Hill A, Belch JJ, Struthers AD. Allopurinol improves endothelial dysfunction in chronic heart failure. Circulation 2002;106:221-226. (Pubitemid 34761303)
40. Doehner W, Schoene N, Rauchhaus M, Leyva-Leon F, Pavitt DV, Reaveley DA, Schuler G, Coats AJ, Anker SD, Hambrecht R. Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: results from 2 placebocontrolled studies. Circulation 2002;105:2619-2624. (Pubitemid 34596038)
41. Clarke R, Shipley M, Lewington S, Youngman L, Collins R, Marmot M, Peto R. Underestimation of risk associations due to regression dilution in long-term follow-up of prospective studies. Am J Epidemiol 1999;150:341-353. (Pubitemid 29383482)